Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04423939 · ClinicalTrials.gov registry record · NA
ACT to Reduce Morbidity and Mortality in Hematopoietic Stem Cell Transplant (HCT) Patients
A NA study, sponsored by Duke University.
- Completed
- Registry status
- NA
- Development phase
- 33
- Enrollment target
NCT04423939 is a NA study that has completed, run by Duke University. The registered enrollment target is 33 participants.
The verdict
NCT04423939, a NA study, has completed, sponsored by Duke University.
- COMPLETED
- Registry status
- NA
- Development phase
- 33 participants
- Enrollment target
Study Summary
This is a research study to develop and test a novel protocol to reduce physical and psychological vulnerabilities that contribute to treatment intolerance and treatment-related morbidity and mortality among hematopoietic stem cell transplant (HCT) patients. When the participant enrolls in this study, they will be asked to participate in acceptance and commitment therapy (ACT) as well as complete in-person physical function tests and a cognitive test. They will also receive training on how to use iOS devices (e.g. iPad, iPhone) and activity trackers (e.g. Apple Watch), which will be provided to them during the duration of study participation. The study team will ask you to complete multiple surveys about emotional and cognitive function, diet and social support, and ask the participant to provide feedback about the treatment (e.g., what they liked or did not like). The study team will also ask the participant to provide stool samples for analysis of the bacteria in intestines, skin surface swabs for analysis of the bacteria on skin and blood samples for analysis of biomarkers and metabolites. Biomarkers and metabolites are molecular and cellular parts that deal with genetic makeup, like DNA, RNA, protein, and/or other naturally occurring substances that may be associated with transplant outcomes. Participants can expect to be enrolled in this study for 3 years.
Interventions
- BEHAVIORAL Acceptance and Commitment Therapy (ACT)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2020-10-14 |
| Est. Completion | 2025-02-01 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04423939
The ClinicalTrials.gov registry entry for NCT04423939 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Duke University, which has 1,725 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Acceptance and Commitment Therapy (ACT) is the first listed.
NCT04423939 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04423939 about?
NCT04423939 is a clinical study titled "ACT to Reduce Morbidity and Mortality in Hematopoietic Stem Cell Transplant (HCT) Patients". This is a research study to develop and test a novel protocol to reduce physical and psychological vulnerabilities that contribute to treatment intolerance and treatment-related morbidity and mortality among hematopoietic stem cell transplant (HCT) patients. When the participant enrolls in this stud...
What is the current status of trial NCT04423939?
This trial is currently completed. It is a NA study. The enrollment target is 33 participants. The study started on 2020-10-14. Estimated completion is 2025-02-01.
What interventions are being tested in trial NCT04423939?
The interventions under investigation include: Acceptance and Commitment Therapy (ACT) (BEHAVIORAL).
Who is sponsoring clinical trial NCT04423939?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.